Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.

Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, Schapira AH, Simons JP, El-Andaloussi S, Alvarez-Erviti L. · 2014

Read Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. by Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, Schapira AH, Simons JP, El-Andaloussi S, Alvarez-Erviti L. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4204174.txt.

Introduction

J. Mark Cooper, Lydia Alvarez-Erviti, and eight co-authors used tiny cell sacs to treat Parkinson-like changes in mice in Movement Disorders in 2014. Parkinson's disease involves clumps of a protein called alpha-synuclein in brain cells. Silencing RNA that lowers this protein could slow the disease, but getting such RNA into the brain is hard.

The team loaded silencing RNA into exosomes, natural carrier sacs, tagged with a rabies virus protein that homes to nerve cells. Injected into the bloodstream, the sacs cut alpha-synuclein message and protein across the brains of normal mice within days. In transgenic mice that form clumps, treatment lowered protein levels and clearly reduced aggregates inside neurons, including in the substantia nigra. The work shows a blood-borne route to gene silencing in the brain.

Catalog record

CREATORCooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, Schapira AH, Simons JP, El-Andaloussi S, Alvarez-Erviti L.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4204174

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice By J Mark Cooper, PB Oscar Wiklander, Joel Z Nordin, Raya Al-Shawi, Matthew J Wood, Mansi Vithlani, Anthony H V Schapira, J Paul Simons, Samir El-Andaloussi, Lydia Alvarez-Erviti Published in: Movement Disorders DOI: 10.1002/mds.25978 ABSTRACT Abstract Alpha-synuclein (α-Syn) aggregates are the main component of Lewy bodies, which are the characteristic pathological feature in Parkinson's disease (PD) brain. Evidence that α-Syn aggregation can be propagated between neurones has led to the suggestion that this mechanism is responsible for the stepwise progression of PD pathology. Decreasing α-Syn expression is predicted to attenuate this process and is thus an attractive approach to delay or halt PD progression. We have used α-Syn small interfering RNA (siRNA) to reduce total and aggregated α-Syn levels in mouse brains. To achieve widespread delivery of siRNAs to the brain we have peripherally injected modified exosomes expressing Ravies virus glycoprotein loaded with siRNA. Normal mice were analyzed 3 or 7 days after injection. To evaluate whether this approach can decrease α-Syn aggregates, we repeated the treatment using transgenic mice expressing the human phosphorylation-mimic S129D α-Syn, which exhibits aggregation. In normal mice we detected significantly reduced α-Syn messenger RNA (mRNA) and protein levels throughout the brain 3 and 7 days after treatment with RVG-exosomes loaded with siRNA to α-Syn. In S129D α-Syn transgenic mice we found a decreased α-Syn mRNA and protein levels throughout the brain 7 days after injection. This resulted in significant reductions in intraneuronal protein aggregates, including in dopaminergic neurones of the substantia nigra. This study highlights the therapeutic potential of RVG-exosome delivery of siRNA to delay and reverse brain α-Syn pathological conditions. © 2014 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. Keywords: α-Syn, RVG-exosomes, siRNA, transgenic mice INTRODUCTION Combined with the ubiquitous presence of alpha-synuclein (α-Syn) aggregates in Lewy bodies (LBs), the finding of mutations in and multiplications of the α-Syn gene in familial Parkinson's disease (PD) all point to the central role of α-Syn in PD pathogenesis.1 In 2003, Braak and colleagues2 described the staging of PD pathology based on the progression of α-Syn pathology from the brainstem to the cortex, consistent with the pathological propagation along specific neural pathways,2 although this is not a feature observed in all PD patients.3 Given the central role of α-Syn in PD pathology, strategies to decrease the expression of α-Syn in neurons are attractive approaches to delay PD progression. Although gene therapy is a powerful tool to down-regulate the expression of α-Syn,4 one of the major challenges for clinical application is the development of a safe and efficient vehicle to deliver the therapy to the brain. The brain is a particularly difficult target for drugs of all classes because the blood–brain barrier excludes most drugs with a size greater than 400 Da.5 Furthermore, delivery of the therapy throughout the brain is required because of the widespread nature of the α-Syn pathology in PD. Gene therapy approaches used in clinical trials have involved local delivery of viral vectors containing complementary DNA (cDNA) encoding for a specific protein.6 However, these are limited by the requirement for stereotactic surgery and delivery restricted to a limited anatomically defined brain region. Although transvascular gene therapy using liposomes has been used in animal models,7 immune activation mediates the rapid clearance of the vehicle and concomitant decrease in efficacy when liposomes are re-administered, limiting the duration of the therapy. To overcome these limitations, we have developed a system that uses systemic administration of modified exosomes for nucleic acid delivery to the brain.8 Exosomes are extracellular vesicles (40-120 nm) of endocytic origin released by numerous cell types that act as natural carriers of messenger RNA (mRNA), microRNA, and proteins between cells.9 We have previously developed modified exosomes that specifically target the brain by expressing a brain-targeting peptide (rabies virus glycoprotein peptide; RVG) in the extra-exosomal N-terminus of Lamp2b, a protein found abundantly in the membrane of exosomes derived from primary dendritic cells. Previously we demonstrated that intravenous injection of RVG-exosomes containing small interfering RNA (siRNAs) into normal mice led to the targeted silencing of Beta-secretase 1 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in the brain highlighting its potential therapeutic value for neurological diseases8. To evaluate the potential of this approach for PD treatment we have assessed the ability of RVG-exosomes loaded with siRNA-targeted for α-Syn to decrease α-Syn and its aggregates in the brains of mice. METHODS Cell Culture and Exosome Purification Murine dendritic cells harvested from bone marrow were cultured in complete medium.8 Cells were transfected after 4 days with 5 µg RVG-Lamp2b plasmid and 5 µL of TransIT LT1 transfection reagent (Mirus Bio). Cell culture medium was changed on day 7, cell culture supernatant harvested after 24 hours, and exosomes isolated by serial centrifugation. Exosomes were resuspended in 0.1 M ammonium acetate. Exosome Treatment of Mice All the experiments were approved by the Swedish Local Board for Laboratory Animals and the UK Home Office. Twelve- to 14-week-old normal C57BL/6 mice and 20- to 22-week-old C57BL/6 transgenic mice expressing the human S129D α-Syn cDNA under the PrP promoter were used for experiments. One hundred fifty micrograms of α-Syn siRNA was electroporated into 150 µg siRNA RVG-exosomes, centrifuged and resuspended in 80 µL of 5% glucose immediately before tail vein injection. Animals were analyzed 3 or 7 days after injection. Alpha-Synuclein Analysis Alpha-synuclein protein differential solubility and total levels were analyzed by western blotting.10 Alpha-synuclein mRNA levels were analyzed by quantitative polymerase chain reaction (qPCR).10 Presence of α-Syn aggregates was analyzed by ThioS and immunohistochemical staining.11 Detailed methods and statistical analyses can be found in the Supplementary Data. RESULTS In Vitro Validation of siRNAs Against Alpha-Synuclein Three different siRNA sequences (siRNA1, 2, and 3) were designed to the coding sequence common to mouse and human α-Syn (Supplemental Data Table 1) to down-regulate their expression without targeting beta or gamma-synuclein (Supplemental Data Table 2). The ability of these siRNAs to knock down wild-type mouse α-Syn was assessed in human SH-SY5Y cells expressing mouse α-Syn-HA (mSyn-SHSY5Y). Using conventional lipofection reagents, we demonstrated a decrease in the total α-Syn mRNA in cells treated with each of the three siRNAs relative to controls (13%, 45%, and 55% decrease, respectively), although this was only statistically significant for siRNA2 and siRNA3 (Fig. 1A). The decrease in ectopic mouse α-Syn protein level was greater than the decrease in mRNA levels; significant decreases were obtained with all three siRNAs (45%, 70%, and 80% decrease, respectively) (Fig. 1B). The experiments were repeated using RVG-exosomes to deliver the siRNAs to the cells. RVG-exosomes were loaded with the three different siRNAs and added to the mSyn-SHSY5Y cell culture medium. After 72 hours, all three siRNAs delivered by RVG-exosomes reduced total α-Syn mRNA (55%, 65%, and 80% decrease, respectively), and protein (64%, 68%, and 85% decrease, respectively) levels (Fig. 1C, D). Small interfering RNA3 was selected as the most efficient sequence. These results validated the use of RVG-exosomes for siRNA delivery and suggested a higher efficiency of RVG-exosomes than a conventional lipofection agent (Supplemental Data Fig. 1).Thus, we next set out to investigate the feasibility of this approach to silence α-Syn in vivo. [Figure: Analysis

Read the complete text